BIVI

BioVie Inc. [BIVI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BIVI Stock Summary

Top 10 Correlated ETFs

BIVI

Top 10 Correlated Stocks

BIVI

In the News

BIVI Financial details

Company Rating
-
Market Cap
28.04M
Income
-43.45M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
15 Apr 2024
P/E
-0.87
Forward P/E
-
PEG
-0.3
P/S
-
P/B
6.23
P/C
-
P/FCF
-1.12
Quick Ratio
1.61
Current Ratio
1.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.19
EPS next Y
-
EPS next Q
-
EPS this Y
68.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-24.14%
-
-
-
-
SMA20
-16.83%
SMA50
-40.14%
SMA100
-17.62%
Inst Own
-
Inst Trans
-
ROA
-227%
ROE
-305%
ROC
-4.47%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.445-8.69
52W High
-
52W Low
-
RSI
32.72
Rel Volume
0.23
Avg Volume
2.58M
Volume
595.24K
Perf Week
-17.78%
Perf Month
-40.08%
Perf Quarter
-45.99%
Perf Half Y
-56.73%
-
-
-
-
Beta
1.213
-
-
Volatility
0.11%, 0.21%
Prev Close
-9.2%
Price
1.48
Change
-11.9%

Something similar

Top by Market Cap
ABEC.DE
EMBASSY.NS
BRH.DE
AAPL
MSF.DE
Top Correlated ETFs
PXJ
OIH
XES
HDRO
SZK
Top Correlated Stocks
MTEK
GEVO
BW
OPTT
NVX
Similar Market Cap
QNTO
PCCT
CNBZ
KWAC
PIGI.L

Company Profile

Healthcare Biotechnology
  • Volume Average 2.58M
  • Market Capitalization 28.04M
  • Employee 18
  • CEO Mr. Cuong Viet Do M.B.A.
  • Headquarters Carson City,NV,US
  • IPO Date 2020-09-18
  • Website https://bioviepharma.com

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.